Drugs / IMA202
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03441100 | May 2019 → Jun 2022 | refractory malignant neoplasm | Immatics US, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2021-03-17 | Immatics Biotechnologies GmbH | Results Immatics Presents Data Update on Dose Escalation from Ongoing ACTengine® Cell Therapy Programs immatics.com ↗
Clinical observations were consistent with observed robust engraftment, persistence and tumor infiltration of infused ACTengine® T cells. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2021-03-17 | Immatics Biotechnologies GmbH | Immatics Presents Data Update on Dose Escalation from Ongoing ACTengine® Cell Therapy Programs immatics.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IMA202 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03441100 ↗ |
| Modality | Cell therapy | “TCR-engineered T Cells” NCT03441100 ↗ |
| Route | Intravenous | “One dose of IMA202 product will be infused intravenously.” NCT03441100 ↗ |